Earnings Outlook For Relmada Therapeutics
Portfolio Pulse from Benzinga Insights
Relmada Therapeutics (NASDAQ:RLMD) is set to release its latest quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $-0.91. The company's past performance shows a pattern of beating EPS estimates, which has sometimes resulted in an increase in share price. However, the stock has been down 45.16% over the last 52-week period.
November 07, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Relmada Therapeutics is expected to report an EPS of $-0.91. The company has a history of beating EPS estimates, which could potentially lead to a short-term increase in share price. However, the stock has been down 45.16% over the last year.
Relmada Therapeutics has a history of beating EPS estimates, which has sometimes resulted in a short-term increase in share price. However, the overall trend for the stock has been negative over the past year, with a 45.16% decrease. This could potentially dampen any positive impact from an earnings beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100